HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTI-PLAQUE INGREDIENT REVIEW BY FDA'S PLAQUE SUBCOMMITTEE

This article was originally published in The Rose Sheet

Executive Summary

ANTI-PLAQUE INGREDIENT REVIEW BY FDA'S PLAQUE SUBCOMMITTEE initially will include 12 single ingredients and four combinations, OTC Plaque Products Subcommittee Acting Chair Robert Genco, DDS/PhD, State University of New York School of Medicine, reported at a June 28-29 meeting. The subcommittee is charged with reviewing the safety and efficacy and risk/benefit of anti-plaque ingredients ("The Rose Sheet" Aug. 9, 1993, p. 1). Genco said the committee plans to review single ingredients when used in combination products at a later date.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel